DOCSLIB.ORG

Typical SCID and Newborn Screening for SCID and T Cell Defects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Typical SCID and Newborn Screening for SCID and T Cell Defects Typical SCID and Newborn Screening for SCID and T Cell Defects Jennifer Puck, MD [email protected] Department of Pediatrics University of California San Francisco and Benioff Children’s Hospital Smith Cardiovascular Research Institute San Francisco, California Disclosure Spouse employed by InVitae, Inc., a clinical gene sequencing company. NBS Case: term infant, 0 TREC, 473 Actin Low total lymphocytes T- B+ NK+ No naïve T cells Severe Combined Immunodeficiency, SCID, Before Newborn Screening • Rare; many genes. • Healthy at birth, but get recurrent, severe infections, failure to thrive. • High mortality in first year. • Absent or low T cells. • Absent or non-functional B cells. • Possible cure by bone marrow transplant from a healthy matched donor (first in 1968). David Veer (1971-1984), Texas Children’s Hospital h8p://www.wired.com/news/images/full/BuBBleBoy3_f.jpg Disclosures and Gratitude State of CA, NewBorn screening immunology expert Baxter Inc, ImmunogloBulin clinical trial Research Support from: Jeffrey Modell Foundaon, Primary Immunodeficiency Center NIH NICHD, NIAID DHHS Maternal and Child Health Bureau CDC NewBorn Screening Branch, Division of Lab Sciences TREC: T Cell Receptor Excision Circle, a Biomarker for Thymic T Cell Production • Normal diverse T cell repertoire is made By cung and pasQng alternate DNA secQons of receptor genes • Excised DNA forms T Cell Receptor Excision Circles (TRECs) as a Byproduct. • TRECs can Be detected By PCR. TCRD locus Vα V δRec Dδ Jδ Cδ ΨJα Jα Cα J Dδ δ // // // // Cδ TCRA locus // TREC PCR across joint SCID Newborn Screening, 2008: Wisconsin 2008 Screening Not screening DHHS Sec. Advis. Commiee: SCID nominated for newborn screening SCID Newborn Screening, December 2009: 3 states, Navajo Nation, Puerto Rico 2008 2009 2009 Screening 2009 Not screening CDC and JMF Grants for Pilot SCID Screening in response to Sec. Advis Commiee refusal due to no proven screening test SCID Newborn Screening, December 2010: 5 states, Navajo Nation, Puerto Rico 2008 2009 2010 2010 2009 Screening 2009 Not screening DHHS Sec. Advis. Commiee approves SCID as a disease for newborn screening. California and New York add 750,000 births/year. SCID Newborn Screening, December 2011: 6 states, Navajo Nation 2008 2009 2011 2010 2011 2010 2009 2010, Screening stopped Not screening Louisiana, Puerto Rico stopped when pilot funds ran out SCID Newborn Screening, December 2012: 11 states, Navajo Nation 2008 2009 2011 2010 2011 2012 2010 2012 2009 2012 2012 2010, Screening stopped 2012 Not screening SCID Newborn Screening, December 2013: 17 states, Navajo Nation 2013 2008 2010 2009 2013 2011 2011 2013 2013 2013 2013 2012 2010 2012 2009 2012 2012 2010, Screening 2008-2012 stopped Screening 2013-2015 2012 Not screening 11 NBS programs pool data from 3 million infants screened. Kwan et al., JAMA 2014 SCID Newborn Screening, December 2014: 27 states, Navajo Nation 2014 2014 2013 2014 2008 2010 2009 2013 2011 2014 2013 2011 2014 2013 2014 2013 2013 2012 2014 2014 2010 2012 2014 2009 2014 2012 2012 2010, Screening 2008-2012 stopped Screening 2013-2015 2012 Not screening US FDA approved SCID screening assay (PerkinElmer) SCID Newborn Screening, December 2015: 28 states, Navajo Nation 2014 2014 2013 2014 2008 2010 2009 2013 2011 2014 2013 2011 2014 2013 2014 2013 2013 2012 2014 2014 2010 2012 2014 2009 2015 2015 2015 2014 2012 2012 2010, Screening 2008-2012 stopped Screening 2013-2015 2012 Not screening SCID Newborn Screening, September, 2016: 41 states, Navajo Nation and Puerto Rico 2014 2016 2016 2014 2013 2014 2016 2008 2016 2016 2016 2010 2009 2013 2011 2014 2013 2011 2014 2013 2014 2013 2013 2012 2014 2014 2016 2010 2012 2014 2016 2009 2015 2015 2016 2016 2015 2014 2012 2016 2012 2010, Screening 2008-2012 stopped Screening 2013-2015 2012 2016 Screening, 2016 Not screening >85% of USA Births; 93% expected By end of 2016 IniQal TREC TREC >22 Normal assay, DNA TRECs copies/uL of TREC >22 ≤22 blood PosiQve / Repeat β-Acn TREC OK ABnormal with TREC ≤5 California β-Acn β-Acn DAF Bad Regular NBS β-Acn OK TREC NICU Incomplete TREC 6-22 β-Acn Bad Algorithm DAF CBC, lymphocyte subsets by NBS Program Repeat TREC ≤22 Low TREC DAF or Heel x2 at one contract Lab; Incomplete Sck interpreted by Immuno TREC >22 Normal Consultants Not normal: <1,500 T cells or absent Normal: ≥1,500 naïve CD4/CD45RA T cells – Refer to CD3 T cells with Immunodeficiency Center naïve cells IniQal TREC TREC >22 Normal assay, DNA TRECs copies/uL of TREC >22 ≤22 blood PosiQve / Repeat β-Acn TREC OK ABnormal with TREC ≤5 California β-Acn β-Acn DAF Bad Regular NBS β-Acn OK TREC NICU Incomplete TREC 6-22 β-Acn Bad Algorithm DAF CBC, lymphocyte subsets by NBS Program Repeat TREC ≤22 Low TREC DAF or Heel x2 at one contract Lab; Incomplete Sck interpreted by Immuno TREC >22 Normal Consultants Not normal: <1,500 T cells or absent Normal: ≥1,500 naïve CD4/CD45RA T cells – Refer to CD3 T cells with Immunodeficiency Center naïve cells SCID Definition “Classic” SCID pre-NewBorn Screening: • No T cells; no specific anQBody, failure to thrive, thrush, recurrent infecQons. New definiQon with screening needs to Be Based on lab values: • “Typical” SCID: <300/uL autologous T cells; <10% of normal proliferaon to mitogens such as PHA; no producQon of specific anQBodies. Proven with null mutaon(s) in known SCID gene. • “Leaky” SCID (includes Omenn syndrome): 300-1500 T cells or more, But low to absent naïve CD45RA T cells, impaired PHA, hypomorphic mutaon(s) in SCID gene. Many SCID Genes, Distinct T, B, NK profiles • IL2RG (common γ chain, X-linked) T- B+ NK- • JAK3 (γ chain associated Janus kinase) T- B+ NK- • IL7R (IL-7 receptor α chain) T- B+ NK+ • CD45 (membrane tyrosine kinase) T- B+ NK+ • TCRD/E/Z ( TCR CD3 δ,ε,ξ chains) T- B+ NK+ • RAG1/RAG2 T- B- NK+ • DCLRE1C (Artemis) T- B- NK+ • LIG4 (DNA ligase IV) T- B- NK+ • PRKDC (DNA PKcs) T- B- NK+ • ADA (adenosine deaminase) T- B- NK- • AK2 (reticular dysgenesis, deafness) T- B+/- NK+ • TTC7A (multiple bowel atresias) T- B+/- NK+ • RMRP (cartilage hair hypoplasia) T- B+/- NK+ • FOXN1 (nude mouse) T- B+ NK+ • CORO1A (Coronin 1A) T- B+/- NK+ Primary Immune Deficiency Treatment Consortium (PIDTC) >40 USA, Canadian and European Centers from 2009 Uniform data collection Retrospective Study 6902: Cross-sectional evaluation Prospective Study 6901: Natural history, observational Identify factors affecting outcomes of HCT, ERT, or GT 5 year survival for Typical SCID depends more on infection than age at HCT • >3.5 months with active infection worse than any other group. • <3.5 months and >3.5 months with no infection had best survival; • >3.5 months with infection resolved not p<0.001 significantly worse than <3.5 months or uninfected. Pai et al, NEJM, 2014 371:434-46. PIDTC SCID Diagnosis by Screening vs. Infection, Family History % Diagnosed Genotypes of Typical and Leaky SCID Reports from Transplant California, with Centers, no Screening TREC Screening Duke University, European 3½ years, 1.7 ×106 infants centers (estimates) Unknown 3% RAG2 1% DCLRE1C 5% Unknown RMRP 1% 12% TTC7A 1% IL2RG 28% JAK3 7% IL2RG JAK3 6% 50% ADA RAG1 14% ADA 12% 18% IL7R IL7R 10% 15% RAG1 1% Overall Survival ~74% Overall Survival 94% 4 Years of California SCID Newborn Screening (2010-2014) Leaky SCID 2 million infants 3% Idiopathic Typical screened. TCL/Variant SCID SCID 12% 255 flow cytometry 4% 2nd tier tests. (1/8,000 infants) 109/255 had <1500 T Normal T Syndrome 13% cells/uL (43%). cells by flow 1/55,000 Typical and 57% Leaky SCID. Secondary 1/180,000 Idiopathic 5% T Cell Lymphopenia Preterm 6% Non-SCID Conditions: Get Early Diagnosis, Avoid Live Vaccines MulQsystem syndromes with variable T cell deficiency 57% DiGeorge/chromosome 22q11.2 deleon 15% Trisomy 21 3% Ataxia telangiectasia 2% CHARGE syndrome Secondary T lymphopenia 25% Congenital cardiac anomalies 38% Other congenital anomalies 13% Vascular leakage, third spacing, hydrops 3% Neonatal leukemia 3-5% Maternal immunosuppressive medicaons Extreme preterm Birth—T cells Become normal over Qme Idiopathic T lymphopenia—few naïve T cells, no maternal cells, poor immune funcQon, no gene defect at outset (when solved move to correct category) Search for Gene Diagnosis Using Deep Sequencing ProBand DNA Filter to retain variants with: Good sequence quality Capture Fragment, exon add linkers Changes predicted in gene fragments product Sequence Absence in controls both ends of Locaon in gene or pathway of fragments interest, or in gene expressed in a Qssue of interest Raw data: short Presence in relaves according to end reads, expected inheritance paern; bi-direconal variants in same gene in similarly affected, unrelated individuals Align to reference sequence; List variants Damage to protein funcQon Initial Clinical Findings • Leaky SCID: 0 TRECs, low T cells, B+, NK+, poor PHA • Microcephaly • Hypertelorism • ABnormal nasal creases • Neonatal tooth • Decreased tone • Desquamang rash • HirsuQsm, loose skin with extra folds • ABsent corpus callosum Exome Trio: De novo BCL11b het missense N441K. Normal human cord blood CD34+ differentiation after transduction with lentiviruses Empty GFP, Patient mutant Bcl11b (N441K) + GFP, or Bcl11b-siRNA + GFP GFP GFP 25 mut 16 mut siRNA siRNA 14 * 20 12 * 10 15 * 8 10 6 * 4 %GFP+ CD19+cells 5 %GFP+ CD3+ cells 2 0 0 0 5 10 15 20 25 30 0 5 10 15 20 25 30 Days in co-culture on OP9 monolayers Days in co-culture on OP9-DL1 monolayers * p < 0.05, GFP v/s mut and GFP v/s siRNA Mut Bcl11b and Bcl11-b siRNA do not affect B cell development, but abrogate T cell development on OP9 cells.
Load more

Recommended publications
  • Our Immune System (Children's Book)
    OurOur ImmuneImmune SystemSystem A story for children with primary immunodeficiency diseases Written by IMMUNE DEFICIENCY Sara LeBien FOUNDATION A note from the author The purpose of this book is to help young children who are immune deficient to better understand their immune system. What is a “B-cell,” a “T-cell,” an “immunoglobulin” or “IgG”? They hear doctors use these words, but what do they mean? With cheerful illustrations, Our Immune System explains how a normal immune system works and what treatments may be necessary when the system is deficient. In this second edition, a description of a new treatment has been included. I hope this book will enable these children and their families to explore together the immune system, and that it will help alleviate any confusion or fears they may have. Sara LeBien This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SECOND EDITION COPYRIGHT 1990, 2007 IMMUNE DEFICIENCY FOUNDATION Copyright 2007 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Our Immune System may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 40 West Chesapeake Avenue, Suite 308, Towson, MD 21204, USA; or by telephone at 1-800-296-4433.
    [Show full text]
  • Understanding the Immune System: How It Works
    Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
    [Show full text]
  • A Novel BCMA/CD3 Bispecific T-Cell Engager for the Treatment
    OPEN Leukemia (2017) 31, 1743–1751 www.nature.com/leu ORIGINAL ARTICLE A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo S Hipp1, Y-T Tai2,3, D Blanset4, P Deegen5, J Wahl5, O Thomas5, B Rattel5, PJ Adam1, KC Anderson2,3 and M Friedrich5 B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein that is expressed on malignant plasma cells of multiple myeloma (MM) patients and therefore is an ideal target for T-cell redirecting therapies. We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ε (BI 836909) and studied its therapeutic impacts on MM. BI 836909 induced selective lysis of BCMA- positive MM cells, activation of T cells, release of cytokines and T-cell proliferation; whereas BCMA-negative cells were not affected. Activity of BI 836909 was not influenced by the presence of bone marrow stromal cells, soluble BCMA or a proliferation-inducing ligand (APRIL). In ex vivo assays, BI 836909 induced potent autologous MM cell lysis in both, newly diagnosed and relapsed/ refractory patient samples. In mouse xenograft studies, BI 836909 induced tumor cell depletion in a subcutaneous NCI-H929 xenograft model and prolonged survival in an orthotopic L-363 xenograft model. In a cynomolgus monkey study, administration of BI 836909 led to depletion of BCMA-positive plasma cells in the bone marrow. Taken together, these results show that BI 836909 is a highly potent and efficacious approach to selectively deplete BCMA-positive MM cells and represents a novel immunotherapeutic for the treatment of MM.
    [Show full text]
  • Immunology 101
    Immunology 101 Justin Kline, M.D. Assistant Professor of Medicine Section of Hematology/Oncology Committee on Immunology University of Chicago Medicine Disclosures • I served as a consultant on Advisory Boards for Merck and Seattle Genetics. • I will discuss non-FDA-approved therapies for cancer 2 Outline • Innate and adaptive immune systems – brief intro • How immune responses against cancer are generated • Cancer antigens in the era of cancer exome sequencing • Dendritic cells • T cells • Cancer immune evasion • Cancer immunotherapies – brief intro 3 The immune system • Evolved to provide protection against invasive pathogens • Consists of a variety of cells and proteins whose purpose is to generate immune responses against micro-organisms • The immune system is “educated” to attack foreign invaders, but at the same time, leave healthy, self-tissues unharmed • The immune system can sometimes recognize and kill cancer cells • 2 main branches • Innate immune system – Initial responders • Adaptive immune system – Tailored attack 4 The immune system – a division of labor Innate immune system • Initial recognition of non-self (i.e. infection, cancer) • Comprised of cells (granulocytes, monocytes, dendritic cells and NK cells) and proteins (complement) • Recognizes non-self via receptors that “see” microbial structures (cell wall components, DNA, RNA) • Pattern recognition receptors (PRRs) • Necessary for priming adaptive immune responses 5 The immune system – a division of labor Adaptive immune system • Provides nearly unlimited diversity of receptors to protect the host from infection • B cells and T cells • Have unique receptors generated during development • B cells produce antibodies which help fight infection • T cells patrol for infected or cancerous cells • Recognize “foreign” or abnormal proteins on the cell surface • 100,000,000 unique T cells are present in all of us • Retains “memory” against infections and in some cases, cancer.
    [Show full text]
  • Regulatory T Cell Research
    Regulatory T cell research Unique kits for cell isolation Harmonized cell culture and expansion tools Convenient functional assay tools Germany/Austria/ Benelux France Nordics and Baltics South Korea Switzerland Miltenyi Biotec B.V. Miltenyi Biotec SAS Miltenyi Biotec Norden AB Miltenyi Biotec Korea Co., Ltd Reliable flow cytometry analysis Miltenyi Biotec GmbH Schipholweg 68 H 10 rue Mercoeur Scheelevägen 17 Arigi Bldg. 8F Friedrich-Ebert-Straße 68 2316 XE Leiden 75011 Paris, France 223 70 Lund 562 Nonhyeon-ro 51429 Bergisch Gladbach The Netherlands Phone +33 1 56 98 16 16 Sweden Gangnam-gu Germany [email protected] Fax +33 1 56 98 16 17 [email protected] Seoul 06136, South Korea Phone +49 2204 8306-0 Customer service [email protected] Customer service Sweden Phone +82 2 555 1988 Fax +49 2204 85197 The Netherlands Phone 0200-111 800 Fax +82 2 555 8890 [email protected] Phone 0800 4020120 Italy Fax 046-280 72 99 [email protected] Fax 0800 4020100 Miltenyi Biotec S.r.l. Customer service Denmark USA/Canada Customer service Belgium Via Persicetana, 2/D Phone 80 20 30 10 Spain Miltenyi Biotec Inc. Phone 0800 94016 40012 Calderara di Reno (BO) Fax +46 46 280 72 99 Miltenyi Biotec S.L. 2303 Lindbergh Street Fax 0800 99626 Italy Customer service C/Luis Buñuel 2 Auburn, CA 95602, USA Customer service Luxembourg Phone +39 051 6 460 411 Norway, Finland, Iceland, Ciudad de la Imagen Phone 800 FOR MACS Phone 800 24971 Fax +39 051 6 460 499 and Baltic countries 28223 Pozuelo de Alarcón (Madrid) Phone +1 530 888 8871 Fax 800 24984 [email protected] Phone +46 46 280 72 80 Spain Fax +1 877 591 1060 Fax +46 46 280 72 99 Phone +34 91 512 12 90 [email protected] China Japan Fax +34 91 512 12 91 Miltenyi Biotec Technology & Miltenyi Biotec K.K.
    [Show full text]
  • The Anatomy of T-Cell Activation and Tolerance Anna Mondino*T, Alexander Khoruts*, and Marc K
    Proc. Natl. Acad. Sci. USA Vol. 93, pp. 2245-2252, March 1996 Review The anatomy of T-cell activation and tolerance Anna Mondino*t, Alexander Khoruts*, and Marc K. Jenkins Department of Microbiology and the Center for Immunology, University of Minnesota Medical School, 420 Delaware Street S.E, Minneapolis, MN 55455 ABSTRACT The mammalian im- In recent years, it has become clear that TCR is specific for a self peptide-class I mune system must specifically recognize a full understanding of immune tolerance MHC complex) T cell that will exit the and eliminate foreign invaders but refrain cannot be achieved with reductionist in thymus and seed the secondary lymphoid from damaging the host. This task is vitro approaches that separate the individ- tissues (3, 4). In contrast, cortical CD4+ accomplished in part by the production of ual lymphocyte from its in vivo environ- CD8+ thymocytes that express TCRs that a large number of T lymphocytes, each ment. The in vivo immune response is a have no avidity for self peptide-MHC bearing a different antigen receptor to well-organized process that involves mul- complexes do not survive and die by an match the enormous variety of antigens tiple interactions of lymphocytes with each apoptotic mechanism. Cortical epithelial present in the microbial world. However, other, with bone-marrow-derived antigen- cells are essential for the process of pos- because antigen receptor diversity is gen- presenting cells (APCs), as well as with itive selection because they display the self erated by a random mechanism, the im- nonlymphoid cells and their products. The peptide-MHC complexes that are recog- mune system must tolerate the function of anatomic features that are designed to op- nized by CD4+ CD8+ thymocytes and also T lymphocytes that by chance express a timize immune tolerance toward innocuous provide essential differentiation factors self-reactive antigen receptor.
    [Show full text]
  • Vaccine Immunology Claire-Anne Siegrist
    2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.
    [Show full text]
  • Maxpar Human Helper T-Cell
    PRD013-201318 Rev. 7 PRODUCT INFORMATION SHEET Maxpar Human Helper T Cell Phenotyping Panel Kit, 15 Marker—25 Tests Catalog: 201318 Storage: Package size: 25 tests • Antibodies, buffers, and water: 4 °C. Do not freeze. • Cell-ID Intercalator-Ir: –20 °C. Contents: Target Clone Metal Target Clone Metal • Maxpar® Cell Staining Buffer (500 mL) CD196/CCR6 G034E3 141Pr CD161 HP-3G10 159Tb • Maxpar Fix and Perm Buffer (25 mL) CD195/CCR5 NP-6G4 144Nd CD45RO UCHL1 165Ho • Maxpar Water (500 mL) CD8 RPA-T8 146Nd CD25 2A3 169Tm • Cell-IDTM Intercalator-Ir (125 µM; 25 µL) CD278/ICOS C398.4A 151Eu CD185/CXCR5 RF8B2 171Yb • Maxpar antibodies (see table for panel)* CD45RA HI100 153Eu CD4 SK3 174Yb CD3 UCHT1 154Sm CD279/PD-1 EH12.2H7 175Lu * The antibodies are provided in individual tubes, not a pre-mixed cocktail. CD183/CXCR3 G025H7 156Gd CD127 A019D5 176Yb CD194/CCR4 L291H4 158Gd Technical Information Description: The Maxpar Human Helper T Cell Phenotyping Panel Kit is for the identification and phenotyping of human CD4+ helper T cell subsets, including T helper 1 (TH1), TH2, TH17, TH22, T follicular helper (TFH), and T regulatory (TREG). Differentiation of CD4+ T cells into functionally distinct helper T subsets is essential for normal immunoregulation. These subsets are specified by extrinsic and intrinsic cues, and the resultant cell populations acquire stable phenotypes defined by the expression of signature cytokines, master regulator transcription factors, and characteristic cell surface phenotypes. Originally, CD4+ T cells were viewed as having only two major fates: 1) TH1 cells, which express T-bet and selectively produce interferon IFNγ and 2) TH2 cells, which express Gata3 and produce interleukin 4 (IL-4).
    [Show full text]
  • Peripheral T-Cell Lymphoma As an Elusive Cause of Progressive Eosinophilic Myocarditis Dylan Mart, MD; Jacob Luty, M.D.; Cristina Fuss, M.D.; Rebecca Harrison, M.D
    Diagnosis Under Pressure Peripheral T-Cell Lymphoma as an Elusive Cause of Progressive Eosinophilic Myocarditis Dylan Mart, MD; Jacob Luty, M.D.; Cristina Fuss, M.D.; Rebecca Harrison, M.D. Department of Medicine, Oregon Health and Science University Introduction Discussion Eosinophilic myocarditis (EM) is a rare cause of progressive PTCL describes a collection of disease entities with no defining myocardial dysfunction that has a broad array of inciting diseases clinical or phenotypic features, and constitute 4-10% of NHL 1 processes and many distinct complications. An elusive cause of EM is overall . There is an elevated incidence in Asian populations, as PTCL constitutes approximately 20% of all NHL2 presenting in that peripheral T-cell lymphoma (PTCL), a protean entity with varied group. presentations. We present a case of PTCL that defied diagnosis, Presenting symptoms are non-specific: Classic “B symptoms” only stressing the importance of a broad differential for causes of EM. present in 35% of cases3. Extra-nodal involvement is present in 49% of cases, solid organ involvement in 17%. Lab findings: - Elevated LDH ~50% of cases Case - Thrombocytopenia ~25% cases Previously healthy 49 year-old Cantonese woman originally presented for - Anemia ~25% of cases evaluation of chest pressure. Multiple previous presentations for - Eosinophilia – Variable progressive fatigue, workup at that time pertinent for: Histology: - Leukocytosis with prominent eosinophilia (69%) - Pleomorphic cell types, most commonly resembling T-cell - TTE with preserved EF, but demonstrating apical RV thrombus 6 phenotype - Cardiac MR demonstrating circumferential subendocardial late - Variable findings on immunohistochemistry, characteristically gadolinium enhancement lack typical “B” markers, and variably express mature T-cell - BMBx: basic autoimmune & infectious workup negative, markers (CD4,5,8, etc) - FNA of submandibular adenopathy technically suboptimal Adverse prognostic indicators3: Discharged on empiric trial of systemic steroids Microscopic findings in the liver.
    [Show full text]
  • Eosinophils Enable the Antitumour T Cell Response
    RESEARCH HIGHLIGHTS Nature Reviews Immunology | AOP, published online 15 May 2015; doi:10.1038/nri3861 GRANULOCYTES Eosinophils enable the antitumour T cell response Tumour-associated eosinophilia is depletion. Eosinophils sorted from macrophages by eosinophils might frequently observed in patients with TReg cell-depleted tumours produced explain the observed vessel cancer, and eosinophils can directly large amounts of these chemokines, normalization. kill tumour cells in vitro. However, which are potent chemoattractants The restricted access of effector intratumoral eosinophils have for CD8+ T cells, leading the authors T cells into tumours is a major limita- been associated with both good to suggest that tumour-associated­ tion to successful immunotherapy, and bad prognoses in human eosinophils promote T cell chemo­ so the authors investigated whether studies, and mouse models attraction. In support of this model, eosinophils could improve the have not shown a direct effect kinetic studies of tumours showed efficacy of adoptive T cell transfer. of eosinophils on tumour growth. that eosinophil infiltration precedes The transfer of tumour-specific Instead, this study shows that infiltration of CD8+ T cells. CD8+ T cells together with acti- eosinophils are crucial accessory In addition to chemokine vated eosinophils led to greater cells in the antitumour immune production, tumour-associated inhibition of tumour growth response that enable the infiltration eosinophils were shown to promote and increased survival of of CD8+ T cells. vascular normalization of the mice compared with transfer In mice with MO4 melanoma tumour — the conversion of a small of T cells alone in two mouse tumours, the depletion of number of dilated, tortuous blood tumour models.
    [Show full text]
  • Regulatory T Cells Suppress Th17 Cell Ca2+ Signaling in the Spinal Cord During Murine Autoimmune Neuroinflammation
    + Regulatory T cells suppress Th17 cell Ca2 signaling in the spinal cord during murine autoimmune neuroinflammation Shivashankar Othya,1,2, Amit Jairamana,1, Joseph L. Dynesa, Tobias X. Donga, Cornelia Tunea,3, Andriy V. Yeromina, Angel Zavalaa, Chijioke Akunwafoa, Fangyi Chena, Ian Parkera,b, and Michael D. Cahalana,c,2 aDepartment of Physiology & Biophysics, University of California, Irvine, CA 92697; bDepartment of Neurobiology & Behavior, University of California, Irvine, CA 92697; and cInstitute for Immunology, University of California, Irvine, CA 92697 Contributed by Michael D. Cahalan, June 11, 2020 (sent for review April 15, 2020; reviewed by Jason G. Cyster and Stefan Feske) T lymphocyte motility and interaction dynamics with other with several autoimmune and systemic inflammatory diseases, and immune cells are vital determinants of immune responses. Regu- are considered to be the main pathogenic cells in the experimental latory T (Treg) cells prevent autoimmune disorders by suppressing autoimmune encephalomyelitis (EAE) murine model of multiple excessive lymphocyte activity, but how interstitial motility pat- sclerosis (6, 7). However, no studies have yet tracked associations terns of Treg cells limit neuroinflammation is not well understood. between endogenous Th17 and Treg cells in relation to APCs We used two-photon microscopy to elucidate the spatial organi- within the complex inflammatory tissue environment. zation, motility characteristics, and interactions of endogenous A well-established signal transduction pathway links TCR binding Treg and Th17 cells together with antigen-presenting cells (APCs) of peptide-MHC on APCs to proximal signaling events leading to within the spinal cord leptomeninges in experimental autoim- 2+ generation of IP3 and consequent depletion of Ca from the en- mune encephalomyelitis (EAE), an animal model of multiple doplasmic reticulum (ER), mobilization of ER STIM1 proteins to sclerosis.
    [Show full text]
  • T CELL MEMORY Efficient at Migrating to Inflamed Peripheral Tissues
    RESEARCH HIGHLIGHTS T CELL MEMORY efficient at migrating to inflamed peripheral tissues. These data suggest that tissue-resident memory CD8+ T cells markedly outnumber those New insight on old-timers that are recirculating and that our current paradigms of memory T cell Memory T cells ensure that the recirculate between the blood and subsets require revision. immune response is more effective non-lymphoid tissues and respond Cui et al. explored how metabolic against re-infecting pathogens. Two rapidly to re-infecting pathogens. processes regulate longevity in mem- key distinctions between memory A further set of tissue-resident mem- ory CD8+ T cells. They compared + CD8 T cells and their naive counter- ory T (TRM) cells have been described gene expression profiles of naive, parts are crucial for this: first, mem- that are retained in non-lymphoid effector and memory CD8+ T cells ory T cells have distinct migratory tissues and do not recirculate. The and found that the glycerol channel patterns; and second, they survive for relative contribution of each subset to aquaporin 9 (AQP9) was selectively longer. New studies by Steinert et al. immune memory has been unclear; expressed by memory CD8+ T cells. and Cui et al. offer fresh insight into to address this, Steinert et al. devel- These cells were shown to upregulate both of these aspects of memory. oped a quantitative immunofluores- AQP9 in response to stimulation Memory CD8+ T cells have been cence microscopy (QIM) method. with interleukin‑7 (IL‑7) — and, to a divided into distinct subsets on the our current In a mouse model of lymphocytic lesser extent, in response to IL‑15 — basis of putative trafficking and func- paradigms choriomeningitis virus (LCMV) and deficiency of AQP9 impaired the tional properties.
    [Show full text]